Investments in companies that matter
- We invest in the best firms in the healthcare and life sciences sectors
- We offer access to a unique portfolio of innovative companies with both sectorial and geographical diversification
- Managed by an experienced team with a long track record in the alternative investments realm
Korion
Life Sciences
Korion is a specialized venture capital fund focused on investing in the best firms in the Life Sciences sector in the United States, Europe, and Israel.
Korion is a venture capital fund of funds that provides institutional and individual investors with access to unique investment opportunities that are not readily available to most investors.
Korion was founded to invest in the most socially impactful and highest performing firms in the life sciences sector. Our investments span the biomedical, digital health, and medical technology sectors, typically during the early stages of company development.
Aim
Korion has received exclusive access to the best and most specialized firms in the life sciences sector.
Korion Life Sciences invests in a diversified fashion in tier-1 venture capital funds as an accredited investor in the private life sciences sector.
Investors may shy away from the life sciences venture capital sector due to difficulty accessing tier-1 funds, high minimum tickets, and trouble maintaining a well-diversified portfolio. Korion mitigates these issues through a single, diversified, and regulated vehicle.
Investment
Strategy
Korion provides investors exclusive access to tier-1 firms in the LS sector.
Korion evaluates prospective funds across multiple selection criteria: track record, manager experience and team cohesion, leadership capacity in investment rounds, proactivity in investments, and investment value creation within the LS ecosystem.
Diversification is achieved across four areas – (i) sectorial: biotechnology, medtech, and digital healthcare, (ii) geographic: USA, Europe, and Israel, (iii) company developmental stage: seed, early-stage, and late-stage, and (iv) temporal: investing across several fund vintages to reduce economic cycle risk.
By applying this strategy, the risk profile associated with LS VC is vastly reduced while attractive returns are achieved.
Korion’s
Advantages
Korion provides the benefits of a professionally managed venture capital fund, including:
1. Access
Investing in top-tier life sciences venture capital funds requires high minimum tickets and specialized knowledge of the sector. Through Korion you access a portfolio upper echelon funds, all of which are highly oversubscribed.
2. Diversification
Investing directly in life sciences companies carries high risks; Korion provides the diversification that is key to reducing volatility without compromising returns.
3. Cost reduction
Investing directly in the life sciences industry requires vast resources to adequately analyze prospective investments. Entry through a regulated vehicle reduces costs and simplifies management.
4. Impact investing
Over the past decade, impact investment strategies have gained importance. Korion invests with sustainability criteria at our core and we have received article 8 according to the SFDR regulations of the European Union.
Korion
Life Sciences
Korion is a specialized venture capital fund focused on investing in the best firms in the Life Sciences sector in the United States, Europe, and Israel.
Korion is a venture capital fund of funds that provides institutional and individual investors with access to unique investment opportunities that are not readily available to most investors.
Korion was founded to invest in the most socially impactful and highest performing firms in the life sciences sector. Our investments span the biomedical, digital health, and medical technology sectors, typically during the early stages of company development.
Aim
Korion has received exclusive access to the best and most specialized firms in the life sciences sector.
Korion Life Sciences invests in a diversified fashion in tier-1 venture capital funds as an accredited investor in the private life sciences sector.
Investors may shy away from the life sciences venture capital sector due to difficulty accessing tier-1 funds, high minimum tickets, and trouble maintaining a well-diversified portfolio. Korion mitigates these issues through a single, diversified, and regulated vehicle.
Investment
Strategy
Korion provides investors exclusive access to tier-1 firms in the LS sector.
Korion evaluates prospective funds across multiple selection criteria: track record, manager experience and team cohesion, leadership capacity in investment rounds, proactivity in investments, and investment value creation within the LS ecosystem.
Diversification is achieved across four areas – (i) sectorial: biotechnology, medtech, and digital healthcare, (ii) geographic: USA, Europe, and Israel, (iii) company developmental stage: seed, early-stage, and late-stage, and (iv) temporal: investing across several fund vintages to reduce economic cycle risk.
By applying this strategy, the risk profile associated with LS VC is vastly reduced while attractive returns are achieved.
Korion’s
Advantages
Korion provides the benefits of a professionally managed venture capital fund, including:
1. Access
Investing in top-tier life sciences venture capital funds requires high minimum tickets and specialized knowledge of the sector. Through Korion you access a portfolio upper echelon funds, all of which are highly oversubscribed.
2. Diversification
Investing directly in life sciences companies carries high risks; Korion provides the diversification that is key to reducing volatility without compromising returns.
3. Cost reduction
Investing directly in the life sciences industry requires vast resources to adequately analyze prospective investments. Entry through a regulated vehicle reduces costs and simplifies management.
4. Impact investing
Over the past decade, impact investment strategies have gained importance. Korion invests with sustainability criteria at our core and we have received article 8 according to the SFDR regulations of the European Union.